

# Pharmacy BULLETIN BOARD

Retail Issue ■ Monday July 7, 2014

**UriSec® emollient creams and lotions are patient friendly formulations ideal for winter dryness and itchy skin.**

Product	Sizes	Odan Code	Kohl & Frisch Code	McKesson Code	McMahon Code
UriSec® 10% Cream NPN 80005397	75 g	38075	32617	513085	26638401
	120 g	38045	32618	513341	26638301
UriSec® 12% Lotion NPN 00514896	250 mL	230J	48909	115493	26623101
UriSec® 22% Cream NPN 00396125	120 g	220Q	46312	115444	26623201
	225 g	220C	-	153486	26537801
	454 g	220R	46309	848549	26632301
UriSec® 40 Cream NPN 80005531	15 g	45014	114939	003743	-
	30 g	45028	32606	799437	27127401
	100 g	45067	32616	799494	26640001

UriSec® products are prescribed by Dermatologists and Physicians and are used by both patients and hospitals across Canada.

To order, please contact your wholesaler or Odan at 1-800-387-9342 or by e-mail at [info@odanlab.com](mailto:info@odanlab.com). You can also visit our website at [www.odanlab.com](http://www.odanlab.com)



UriSec® is a registered trademark of Odan Laboratories Ltd.

## ■ FROM THE NEWSWIRE ■

**MISSISSAUGA:** Women with HER2-positive metastatic breast cancer in Manitoba will now be able to access a new treatment option through CancerCare Manitoba. The Provincial Oncology Drug Program has approved the addition of KADCYLA® (trastuzumab emtansine) to the CancerCare Manitoba Drug Formulary. CancerCare Manitoba has approved KADCYLA as second line treatment for patients with HER2-positive, unresectable locally advanced or metastatic breast cancer with an ECOG performance status equal to or less than two, who have received prior treatment with trastuzumab plus chemotherapy in the metastatic setting or have disease recurrence during or within six months of completing adjuvant therapy with trastuzumab plus chemotherapy.

**MONTREAL:** Kids with Type 1 Diabetes (T1D) face many difficulties and challenges, including learning to self-inject. But now a new insulin pen from Sanofi Canada has been designed to help these youngsters through the process.

**OTTAWA:** The Government of Canada has language labelling regulations that will help improve the safe use of drugs by making drug labels and packaging information easier to read and understand, as promised in the 2013 Speech from the Throne. The Regulations Amending the Food and Drug Regulations (Labelling, Packaging and Brand Names of Drugs for Human Use) were published in Canada Gazette, Part II and are part of the Plain Language Labelling Initiative. The regulations will gradually be phased into effect, delivering key safeguards.

**OAKVILLE, ON:** As scientific evidence has accumulated, there has been a movement toward lower dose estrogen formulations of combined oral contraceptives, which demonstrate similar efficacy with fewer side effects than higher dose options. Actavis Specialty Pharmaceuticals Co. has announced the Health Canada approval and availability of LOLO™ (ethinyl estradiol and norethindrone acetate tablets), a new low-dose oral contraceptive indicated for the prevention of pregnancy that uses only 10 micrograms (mcg) of estrogen — the lowest dose of any combined oral contraceptive.

**WATERLOO:** Manulife has entered into a three year sponsorship as the Mental Health at Work® Champion of Excellence with Excellence Canada to help improve the mental health of Canadians within the workplace. Manulife will work with Excellence Canada to further promote and administer the program for organizations across Canada.